Skip to main content

Table 1 Baseline characteristics of IMN patients

From: New risk score for predicting progression of membranous nephropathy

  All
Follow-up time (m) 38.73 ± 19.35
Age (years) 56 (15–83)
Female (%) 209 (47.61%)
Albumin (g/l) 23 (8–43)
Proteinuria (g/24 h) 3.98 (1.5–22.98)
eGFR (ml/min/1.73 m2) 100.31 (12.81–155.98)
Microscopic hematuria (%) 260 (59.22%)
Triglyceride (mmol/l) 2.35 (0.70–10.92)
Cholesterol (mmol/l) 7.17 (1.84–16.71)
Uric acid (μmol/l) 357.03 ± 83.38
Serum PLA2R antibody (RU/l) 26.54 (0.52–1040.18)
Pathology
 LM-stages I and II (%) 348 (79.27%)
 LM- ≥ 50% tubulointerstitial lesions (%) 15 (3.42%)
 IF-PLA2R positive staining (%) 80/94 (85.11%)
 IF-IgG1 positive (%) 95/112 (84.82%)
 IF-IgG4 positive (%) 104/112 (92.86%)
 Primary outcomes (%) 36 (8.20%)
 Renal function progression (%)a 24 (5.47%)
 Death (%) 9 (2.05%)
 ESRD (%) 3 (0.68%)
  1. Continuous variables presented as mean ± SD or median (range)
  2. ESRD end-stage renal disease, LM light microscopic, IF immunofluorescence
  3. aRenal progression: a reduction in eGFR greater than or equal to 30% compared with that at renal biopsy